Fusion Pharmaceuticals Management
Management criteria checks 4/4
Fusion Pharmaceuticals' CEO is John Valliant, appointed in Dec 2014, has a tenure of 9.33 years. total yearly compensation is $2.08M, comprised of 28.7% salary and 71.3% bonuses, including company stock and options. directly owns 0.38% of the company’s shares, worth $6.81M. The average tenure of the management team and the board of directors is 2.6 years and 5 years respectively.
Key information
John Valliant
Chief executive officer
US$2.1m
Total compensation
| CEO salary percentage | 28.7% |
| CEO tenure | 9.3yrs |
| CEO ownership | 0.4% |
| Management average tenure | 2.6yrs |
| Board average tenure | 5yrs |
Recent management updates
Recent updates
Fusion Pharmaceuticals' Partnerships Strengthen Long-Term Outlook
Mar 03Health Check: How Prudently Does Fusion Pharmaceuticals (NASDAQ:FUSN) Use Debt?
Jan 30
Fusion Pharmaceuticals initiated at buy at Truist on lead candidate for solid tumors
Sep 16Fusion Pharma doses first patient in phase 1/2 study for solid tumors treatment
Aug 29Will Fusion Pharmaceuticals (NASDAQ:FUSN) Spend Its Cash Wisely?
Aug 10Fusion Pharmaceuticals GAAP EPS of -$0.44 beats by $0.09, revenue of $0.57M beats by $0.46M
Aug 09Fusion Pharma wins FDA nod to start trials for solid tumor candidate
Jun 23We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate
Jan 16We're Not Very Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Rate
Aug 28Fusion Pharma trades higher on early-stage data for cancer therapy
Jun 14We're Hopeful That Fusion Pharmaceuticals (NASDAQ:FUSN) Will Use Its Cash Wisely
Apr 05How Much Of Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Do Institutions Own?
Mar 01Who Has Been Buying Fusion Pharmaceuticals Inc. (NASDAQ:FUSN) Shares?
Jan 25Here's Why We're Not Too Worried About Fusion Pharmaceuticals' (NASDAQ:FUSN) Cash Burn Situation
Dec 21Fusion Pharmaceuticals EPS misses by $0.04
Nov 10Fusion Pharma teams up with AstraZeneca in next-gen radiopharmaceuticals for cancer
Nov 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | US$2m | US$597k | -US$95m |
| Sep 30 2023 | n/a | n/a | -US$91m |
| Jun 30 2023 | n/a | n/a | -US$98m |
| Mar 31 2023 | n/a | n/a | -US$92m |
| Dec 31 2022 | US$3m | US$595k | -US$88m |
| Sep 30 2022 | n/a | n/a | -US$80m |
| Jun 30 2022 | n/a | n/a | -US$76m |
| Mar 31 2022 | n/a | n/a | -US$83m |
| Dec 31 2021 | US$3m | US$597k | -US$81m |
| Sep 30 2021 | n/a | n/a | -US$77m |
| Jun 30 2021 | n/a | n/a | -US$68m |
| Mar 31 2021 | n/a | n/a | -US$86m |
| Dec 31 2020 | US$7m | US$505k | -US$80m |
| Sep 30 2020 | n/a | n/a | -US$75m |
| Jun 30 2020 | n/a | n/a | -US$65m |
| Mar 31 2020 | n/a | n/a | -US$24m |
| Dec 31 2019 | US$1m | US$399k | -US$16m |
Compensation vs Market: John's total compensation ($USD2.08M) is below average for companies of similar size in the US market ($USD5.57M).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
CEO
John Valliant (52 yo)
9.3yrs
Tenure
US$2,081,586
Compensation
Dr. John F. Valliant Ph D, is Founder of Fusion Pharmaceuticals Inc. and its Chief Executive Officer & Director since December 2014. He served as Member of Scientific Advisory Board of Molecular Insight Ph...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 9.3yrs | US$2.08m | 0.38% $ 6.8m | |
| President & Chief Business Officer | 2.6yrs | US$1.41m | 0.015% $ 275.0k | |
| CFO & Compliance Officer | 5.2yrs | US$1.30m | 0.012% $ 223.0k | |
| Chief Technology Officer | 2.4yrs | US$1.42m | 0.045% $ 824.5k | |
| Chief Scientific Officer | 2.4yrs | no data | 0.014% $ 256.2k | |
| Senior Director of Investor Relations & Corporate Communications | no data | no data | no data | |
| Chief Legal Officer | 3.6yrs | no data | no data | |
| Senior Vice President of Business Development | 2.6yrs | no data | no data | |
| Chief of Staff | no data | no data | no data | |
| Executive Vice President of Medical Director & Clinical Development | 2yrs | no data | no data | |
| Chief Medical Officer | 1.4yrs | no data | no data |
2.6yrs
Average Tenure
52.5yo
Average Age
Experienced Management: FUSN's management team is considered experienced (2.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 9.3yrs | US$2.08m | 0.38% $ 6.8m | |
| Independent Chairperson of the Board | 3.5yrs | US$126.49k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$103.49k | 0% $ 0 | |
| Independent Director | 4.3yrs | US$108.24k | 0.067% $ 1.2m | |
| Independent Director | less than a year | US$101.89k | no data | |
| Member of Advisory Board | 5.8yrs | no data | no data | |
| Independent Director | 3yrs | US$98.49k | 0% $ 0 | |
| Member of Advisory Board | 5.8yrs | no data | no data | |
| Member of Advisory Board | 5.8yrs | no data | no data | |
| Member of Advisory Board | 5.8yrs | no data | no data | |
| Member of Advisory Board | 5.8yrs | no data | no data | |
| Independent Director | 3.2yrs | US$97.49k | 0% $ 0 |
5.0yrs
Average Tenure
52yo
Average Age
Experienced Board: FUSN's board of directors are considered experienced (5 years average tenure).